45 related articles for article (PubMed ID: 27813536)
21. Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy.
Chen Z; Cortes JE; Jorgensen JL; Wang W; Yin CC; You MJ; Jabbour E; Kantarjian HM; Medeiros LJ; Hu S
Leukemia; 2016 Jul; 30(7):1606-9. PubMed ID: 26837843
[No Abstract] [Full Text] [Related]
22. Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors.
Wang W; Cortes JE; Lin P; Beaty MW; Ai D; Amin HM; McDonnell TJ; Ok CY; Kantarjian HM; Medeiros LJ; Hu S
Blood; 2015 Oct; 126(14):1699-706. PubMed ID: 26243778
[TBL] [Abstract][Full Text] [Related]
23. Impact of trisomy 8 on treatment response and survival of patients with chronic myelogenous leukemia in the era of tyrosine kinase inhibitors.
Wang W; Cortes JE; Lin P; Khoury JD; Ai D; Tang Z; Tang G; Jorgensen JL; Medeiros LJ; Hu S
Leukemia; 2015 Nov; 29(11):2263-6. PubMed ID: 25931274
[No Abstract] [Full Text] [Related]
24. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
Baccarani M; Deininger MW; Rosti G; Hochhaus A; Soverini S; Apperley JF; Cervantes F; Clark RE; Cortes JE; Guilhot F; Hjorth-Hansen H; Hughes TP; Kantarjian HM; Kim DW; Larson RA; Lipton JH; Mahon FX; Martinelli G; Mayer J; Müller MC; Niederwieser D; Pane F; Radich JP; Rousselot P; Saglio G; Saußele S; Schiffer C; Silver R; Simonsson B; Steegmann JL; Goldman JM; Hehlmann R
Blood; 2013 Aug; 122(6):872-84. PubMed ID: 23803709
[TBL] [Abstract][Full Text] [Related]
25. Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.
Luatti S; Castagnetti F; Marzocchi G; Baldazzi C; Gugliotta G; Iacobucci I; Specchia G; Zanatta L; Rege-Cambrin G; Mancini M; Abruzzese E; Zaccaria A; Grimoldi MG; Gozzetti A; Ameli G; Capucci MA; Palka G; Bernasconi P; Palandri F; Pane F; Saglio G; Martinelli G; Rosti G; Baccarani M; Testoni N;
Blood; 2012 Jul; 120(4):761-7. PubMed ID: 22692507
[TBL] [Abstract][Full Text] [Related]
26. Cytogenetic profile of 1,863 Ph/BCR-ABL-positive chronic myelogenous leukemia patients from the Chinese population.
Mu Q; Ma Q; Wang Y; Chen Z; Tong X; Chen FF; Lu Y; Jin J
Ann Hematol; 2012 Jul; 91(7):1065-72. PubMed ID: 22349721
[TBL] [Abstract][Full Text] [Related]
27. Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IV.
Fabarius A; Leitner A; Hochhaus A; Müller MC; Hanfstein B; Haferlach C; Göhring G; Schlegelberger B; Jotterand M; Reiter A; Jung-Munkwitz S; Proetel U; Schwaab J; Hofmann WK; Schubert J; Einsele H; Ho AD; Falge C; Kanz L; Neubauer A; Kneba M; Stegelmann F; Pfreundschuh M; Waller CF; Spiekermann K; Baerlocher GM; Lauseker M; Pfirrmann M; Hasford J; Saussele S; Hehlmann R;
Blood; 2011 Dec; 118(26):6760-8. PubMed ID: 22039253
[TBL] [Abstract][Full Text] [Related]
28. Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy.
Verma D; Kantarjian H; Shan J; O'Brien S; Estrov Z; Garcia-Manero G; Koller C; Borthakur G; Cortes J
Cancer; 2010 Jun; 116(11):2673-81. PubMed ID: 20499401
[TBL] [Abstract][Full Text] [Related]
29. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia.
Johansson B; Fioretos T; Mitelman F
Acta Haematol; 2002; 107(2):76-94. PubMed ID: 11919388
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia.
Wang W; Chen Z; Hu Z; Yin CC; Li S; Bai S; Bueso-Ramos CE; Medeiros LJ; Hu S
Blood Cancer J; 2016 Nov; 6(11):e490. PubMed ID: 27813536
[No Abstract] [Full Text] [Related]
31. Novel tyrosine kinase inhibitors in chronic myelogenous leukemia.
Jabbour E; Cortes J; Kantarjian H
Curr Opin Oncol; 2006 Nov; 18(6):578-83. PubMed ID: 16988578
[TBL] [Abstract][Full Text] [Related]
32. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
33. [Management of chronic myeloid leukemia for Japanese patients in the era of TKIs].
Usui N
Rinsho Ketsueki; 2014 May; 55(5):497-507. PubMed ID: 24881914
[No Abstract] [Full Text] [Related]
34. Chronic myeloid leukemia: Second-line drugs of choice.
Gambacorti-Passerini C; Aroldi A; Cordani N; Piazza R
Am J Hematol; 2016 Jan; 91(1):67-75. PubMed ID: 26588811
[TBL] [Abstract][Full Text] [Related]
35. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shamroe CL; Comeau JM
Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
[TBL] [Abstract][Full Text] [Related]
36. [Novel therapeutic approach of Ph-positive leukemia: combination of tyrosine kinase inhibitors with other targeted drugs].
Tauchi T
Rinsho Ketsueki; 2013 Jun; 54(6):559-67. PubMed ID: 23823095
[No Abstract] [Full Text] [Related]
37. [Can chronic myeloid leukemia be cured by tyrosine kinase inhibitor?].
Li MQ; Liu ZG
Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):725-8. PubMed ID: 23978030
[No Abstract] [Full Text] [Related]
38. Mutational analysis and overcoming imatinib resistance in chronic myeloid leukemia with novel tyrosine kinase inhibitors.
Mauro MJ
Curr Treat Options Oncol; 2007 Aug; 8(4):287-95. PubMed ID: 18157514
[No Abstract] [Full Text] [Related]
39. Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more.
Cea M; Cagnetta A; Garuti A; Cirmena G; Rocco I; Moran E; Grillo V; Ballestrero A; Patrone F; Nencioni A
J BUON; 2009; 14(4):565-73. PubMed ID: 20148444
[TBL] [Abstract][Full Text] [Related]
40. Monitoring minimal residual disease in patients with chronic myeloid leukemia after treatment with tyrosine kinase inhibitors.
Sahay T; Schiffer CA
Curr Opin Hematol; 2008 Mar; 15(2):134-9. PubMed ID: 18300760
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
